Yuh-Min Chen

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 953 citations

Medicine, Oncology, Pharmacology +10

Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations

Paul K. Paik, Enriqueta Felip, Rémi Veillon et al. · New England Journal of Medicine · 2020 · 854 citations · Full text

Medicine, Oncology, Pharmacology +15

Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia

Qing Lan, Chao A. Hsiung, Keitaro Matsuo et al. · Nature Genetics · 2012 · 354 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

Yi‐Long Wu, Jin Soo Lee, Sumitra Thongprasert et al. · The Lancet Oncology · 2013 · 304 citations

Medicine, Oncology, Pharmacology +12

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Tony Mok, Yi‐Long Wu, Chong‐Jen Yu et al. · Journal of Clinical Oncology · 2009 · 220 citations · Full text

Medicine, Oncology, Pharmacotherapy +12